RecruitingPhase 1NCT07734610

A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)

An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of Nemtabrutinib in Participants With Severe Renal Impairment

Sponsor

Merck Sharp & Dohme LLC

Enrollment

20 participants

Start Date

Sep 17, 2026

Study Type

INTERVENTIONAL

Conditions

Healthy Severe renal impairment.

Summary

The purpose of this study is to learn what happens to nemtabrutinib in a person's body when given to participants with severe kidney disease and to healthy participants.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria6

All participants:
Has a body mass index (BMI) ≥18.0 and ≤40.0 kg/m\^2
Participants with Severe Renal impairment (RI):
The participant has stable renal function as determined by historical measurements.
Healthy volunteers:
Is medically healthy with no clinically significant medical history

Exclusion Criteria4

Renal Impairment Participants:
History of any illness, other than renal impairment, that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
Healthy Matched Control Participants:
History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases. Participants with a remote history of uncomplicated medical events (eg, uncomplicated kidney stones, as defined as spontaneous passage and no recurrence in the last 5 years, or childhood asthma) may be enrolled in the study at the discretion of the investigator

Interested in this trial?

Get notified about updates and connect with the research team.